[{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Innovative Therapies for Children with Cancer Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Innovative Therapies for Children with Cancer Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Innovative Therapies for Children with Cancer Consortium"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Han Xu","sponsor":"UnitedHealthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Han Xu","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Han Xu \/ UnitedHealthcare","highestDevelopmentStatusID":"9","companyTruncated":"Han Xu \/ UnitedHealthcare"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Nationwide Children\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"||Serine-protein kinase ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Topotecan","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"||vasodilators (undefined group)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Topotecan HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Han Xu

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Han Xu

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Topotecan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Small Cell Lung Carcinoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 28, 2025

                          Lead Product(s) : Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : UnitedHealthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Unity Health Toronto

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Unity Health Toronto

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Topotecan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhegmatogenous Retinal Detachment, Autosomal Dominant.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : Topotecan Hydrochloride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          June 11, 2024

                          Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : SP-2577 (seclidemstat) is an oral LSD1 inhibitor, small molecule drug candidate. It is being evaluated in phase 1 /2 clinical trials for the treatment of Ewing sarcoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 22, 2024

                          Lead Product(s) : Seclidemstat,Cyclophosphamide,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastoma. VCN-01, an oncolytic adenovirus expressing hyaluronidase developed by Albumin Shield™ technology.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          September 30, 2022

                          Lead Product(s) : VCN-01,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Unity Health Toronto

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Unity Health Toronto

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Topotecan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vitreoretinopathy, Proliferative.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 31, 2022

                          Lead Product(s) : Topotecan Hydrochloride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical studies for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progress...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 22, 2022

                          Lead Product(s) : Seclidemstat,Cyclophosphamide,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Topotecan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroblastoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 23, 2022

                          Lead Product(s) : Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Innovative Therapies for Children with Cancer Consortium

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Seclidemstat is a novel, oral, reversible inhibitor of the lysine-specific histone demethylase 1 enzyme (LSD1), an enzyme that has been shown to play a key role in the development and progression of certain cancers.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 29, 2021

                          Lead Product(s) : Seclidemstat,Cyclophosphamide,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Salarius lead candidate, SP-2577 (seclidemstat) is currently advancing a Phase 1/2 dose-expansion clinical trial,used as a treatment for pediatric cancers, sarcomas, and other cancers.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 15, 2021

                          Lead Product(s) : Seclidemstat,Cyclophosphamide,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank